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Background and aims: In patients with impaired renal function and macroalbuminuria, cardiovascular
risk factors are highly prevalent, however, whether this is also present in the general population is
unclear. We investigated whether normal-range albuminuria and renal function are associated with
cardiovascular function in the general population.
Methods: In this cross-sectional analysis of the NEO study, urinary albumin-creatinine ratio (UACR),
estimated glomerular filtration rate (eGFR), and intima-media thickness were assessed in all participants
(n¼ 6503), and a random subset underwent MRI for pulse wave velocity (n¼ 2451) and/or cardiac
imaging (n¼ 1138).
Results: Multiple linear regression analysis was performed while adjusting for sex, age, smoking, mean
arterial blood pressure, total body fat, and fasting glucose. After adjustment, albuminuria and renal
function were positively associated with left ventricle (LV) mass index (UACR, 0.941 g/m2 [95% CI:
0.21,1.67] p¼ 0.012; eGFR, 0.748 g/m2 [95% CI: 0.15,1.35] p¼ 0.015) and LV cardiac index (UACR, 0.056 L/
min/m2 [95% CI: 0.00,0.11] p¼ 0.038; eGFR, 0.080 L/min/m2 [95% CI: 0.03,0.13] p¼ 0.001). Albuminuria
showed a weak association with arterial thickness (UACR, 0.003mm [95% CI: 0.00,0.01] p¼ 0.015) and
arterial stiffness (UACR, 0.073m/s [95% CI: 0.01,0.13] p¼ 0.036), but not with renal function. No associ-
ations were observed for LV ejection fraction and LV diastolic function.
Conclusions: Normal-range albuminuria was positively associated with LV mass index, LV cardiac index,
arterial thickness and arterial stiffness. Our findings support the hypothesis that even within normal
range, albuminuria is a marker of cardiovascular health.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic kidney disease (CKD), characterized by renal insuffi-
ciency and macroalbuminuria, is associated with a substantial risk
of cardiovascular morbidity and mortality [1,2]. The exacty mass index; cIMT, carotid
ltration rate; E/A, early filling
ling phase deceleration peak;
; PWV, pulse wave velocity;
, Leiden University Medical
therlands.
.
B.V. This is an open access article umechanism underlying the observed excess of cardiovascular dis-
ease in chronic kidney disease is unknown, and increasing evidence
suggests that this relationship goes beyond indirect associations by
hypertension [3,4]. Macroalbuminuria is commonly used as a
marker of kidney disease progression. Microalbuminuria [5] and
higher levels of albuminuria within ‘normal range’ are associated
with a higher risk of cardiovascular events [6,7]. In non-diabetic
patients, microalbuminuria is considered to reflect endothelial
damage via degradation of the endothelial glycocalyx [8]. This
endothelial glycocalyx degradation could be the biological pathway
that explains the continuous relationship between urinary albumin
excretion and cardiovascular risk. In this case, cardiac remodeling
in advanced renal disease could be preceded by subclinical car-
diovascular changes as a consequence of microalbuminuria.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cardiovascular function in the general population remains unclear.
Better understanding of the relationship between albuminuria and
cardiac remodeling, requires knowledge of associations in the
general population. However, the majority of population-based
studies thus far have focused on the presence of hypertension
[9,10]. Moreover, these studies lacked functional data, such as LV
systolic/diastolic function and arterial stiffness. The aim of this
study is to investigate the association between normal range
albuminuria, renal function, and cardiovascular imaging parame-
ters in the general population. We hypothesize that also albumin-
uria within normal range is a marker of cardiovascular function in
the middle-aged general population. By improving insight into
cardiac remodeling mechanisms in the population at large, pre-
ventative strategies might eventually become feasible to reduce
cardiovascular risk in CKD patients.
2. Materials and methods
2.1. Study population and study design
The Netherlands Epidemiology of Obesity (NEO) study is a
population-based, prospective cohort study designed to investigate
pathways that lead to obesity-related diseases [11]. Men and
women living in the greater area of Leiden (the Netherlands) were
invited to participate in the study if theywere aged between 45 and
65 years and had a self-reported body mass index (BMI) of 27 kg/
m2. In addition, all inhabitants from one municipality (Leiderdorp)
were invited to participate irrespective of their BMI, allowing for a
reference distribution of BMI. Participants with potential contra-
indications for MRI (i.e. metallic devices, or claustrophobia) were
excluded for additional imaging. Of all MRI eligible participants,
approximately 30% were randomly selected to undergo arterial
stiffness measurement, and a second random subset of approxi-
mately 50% had additional cardiovascular magnetic resonance im-
aging as well. All procedures followed in this study were in
accordance with the ethical standards of the responsible commit-
tee on human experimentation (institutional and national) and
with the Helsinki Declaration of 1975, as revised in 2000 [12]. The
Medical Ethical Committee of the Leiden University Medical Center
(LUMC) approved the design of the study and all participants gave
their written informed consent.
2.2. Data collection
Participants were invited to a baseline visit at the NEO study
center of the LUMC after an overnight fasting period. Prior to this
study visit, participants collected their urine over 24 h and
completed a general questionnaire at home to report demographic,
lifestyle and clinical information. The participants were asked to
bring all medications they were using to the study visit. At the
baseline visit, all participants underwent physical examination
including anthropometry and blood pressure measurement. Height
wasmeasuredwith a vertically fixed, calibrated tapemeasure. Body
weight and percent body fat were measured by the Tanita bio
impedance balance (TBF-310, Tanita International Division, UK)
without shoes, and 1 kg was subtracted to correct for the weight of
clothing. BMI was calculated by dividing the weight in kilograms by
the height in meters squared. Brachial blood pressure was
measured in a seated position on the right arm using a validated
automatic oscillometric device (OMRON, Model M10-IT, Omron
Health Care Inc, IL, USA). Blood pressure was measured three times
with 5 min rest between consecutive measurements. The mean
systolic, diastolic and mean arterial ([(2  diastolic blood
pressure) þ systolic blood pressure]/3) blood pressure wascalculated.
2.3. Laboratory measurements
Fasting blood samples were drawn from the antecubal vein after
5min rest of the participant, and were used to determine serum
concentrations of glucose, insulin, triglycerides, creatinine, total
cholesterol HDL, and LDL. Serum creatinine (mg/dl) was used to
calculate the estimated GFR according to the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) formula [13]. For the
measurement of albuminuria, the urinary albumin creatinine ratio
(UACR) was derived from a first morning void. Normal range
albuminuria was defined as UACR of <3mg/mmol (<30mg/g),
microalbuminuria (moderately increased albuminuria) as UACR of
3e30mg/mmol (30e300mg/g), and macroalbuminuria (severely
increased albuminuria) as UACR >30mg/mmol (>300mg/g) [14].
All laboratory analyses were performed in the central clinical
chemistry laboratory of the LUMC [11].
2.4. Carotid intima-media thickness
Carotid intima-media thickness (cIMT) was assessed by ultra-
sonography of the far wall of the left and right common carotid
arteries along a 15mm section 10mm proximal of the bifurcation,
using a 7.5e10MHz linear-array transducer in B-mode setting (Art.
Lab version 2.1, Esaote, Maastricht, The Netherlands).
2.5. Pulse wave velocity and cardiovascular magnetic resonance
imaging
Magnetic resonance imaging was performed on a 1.5 T whole-
body MR scanner (Philips Medical Systems, Best, the Netherlands).
Through-plane flow measurements of the ascending, proximal
descending, mid-descending, and distal descending aorta were
acquired using multislice, one-directional in-plane velocity-
encoded MRI with velocity sensitivity of 150 cm/s. Aortic PWV
was calculated by dividing the aortic path length between the
measurement sites (Dx) by the transit time between the arrival of
the systolic wave front at these sites (Dt), and it is expressed in
meters per second [15].
The entire heart was imaged in short-axis orientation using
electrocardiographically gated breath-hold balanced steady-state
free precession (Repetition Time 3.4ms, Echo Time 1.7ms; Flip
Angle 35; slice thickness 10mm; slice gap 0mm; Field of View
400 400mm; matrix size¼ 256 256). LV mass determined by
the sum of myocardial area times slice thickness multiplied by the
myocardial gravity (1.05 g/ml), and LVmass index was calculated by
dividing LV mass by body surface area (BSA). LV hypertrophy was
defined as LV mass index >84.1 g/m2 for men and >76.4 g/m2 for
women. LV cardiac output was calculated by multiplying stroke
volume by heart rate, and LV cardiac index by dividing LV cardiac
output by body surface area (BSA). LV ejection fraction by dividing
stroke volume by the end-diastolic volume multiplied by 100%. An
electrocardiographically gated gradient-echo sequence with ve-
locity encoding was used to measure blood flow across the mitral
valve (Repetition Time 6.5ms, Echo Time 1ms; Flip Angle 20;
section thickness 8mm, Field of View 350 350mm; matrix size
256 256mm; velocity encoding gradient 150 cm/s). Subsequent
wave-form analysis of mitral inflow pattern was performed,
resulting in the quantification of early (E) and atrial (A) peak filling
velocity, E/A ratio, and the E deceleration peak [16]. Image post
processing was performed with in-house developed software
(MASS and FLOW, Medis, Leiden, the Netherlands) with consensus
between two experienced radiologists. Imaging analysis of the
cIMT, PWV and cardiac MRI group are visualized in Fig. 1B.
Fig. 1. Flow diagram and imaging protocol for the total population, and PWV and cardiac MRI analysis subgroups.
(A) Study flow diagram for the final carotid intima-media thickness (total population), pulse wave velocity subgroup (PWV), and cardiac MRI aubgroup. (B) Overview of the imaging
protocol per analysis group; for the cIMT group, this consisted of carotid ultrasound for the measurement of the intima-media thickness (yellow bar in the B-mode ultrasound image
of the common carotid artery); for the PWV group, this consisted of velocity-encoded MRI of the ascending aorta (red contour) and descending aorta (blue contour) with an imaging
direction similar to the anatomical drawing of the aorta; for the cardiac MRI group, this consisted of a short-axis two-chamber images of heart for the assessment of LV mass index
(LV myocardial area contours in red) and volumetric derived LV systolic function (LV volume shaded in red), and velocity-encoded MRI of the mitral valve for the assessment of LV
diastolic function (mitral valve contour in blue). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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In the NEO study, individuals with a BMI of 27 kg/m2 or higher
were oversampled. First, inhabitants of Leiden and its surround-
ings, between 45 and 65 years of age, and with a self-reported BMI
of 27 kg/m2 or higher, were invited to participate in the NEO study.
In addition, we included a reference population. To that extent, all
inhabitants between 45 and 65 years living in one municipality,
Leiderdorp, were asked to participate irrespective of their BMI. This
resulted in an additional sample of 1671 participants with a BMI
distribution that was similar to the BMI distribution of the general
Dutch population [17]. If inference is made on the general popu-
lation, the over-representation of overweight and obese partici-
pants in the NEO study may introduce bias, because of the skewed
BMI distribution in the NEO population. Weighting towards the
BMI distribution of the general population may solve this problem
[18]. Using the BMI distribution of the reference population, we
calculated weight factors for the NEO population, resulting in a
higher weight factor for participants with a lower BMI [19]. Use of
sampling weights yield results that apply to a population-based
study without oversampling of individuals with a high BMI [20].
UACRwas log-2 transformed to account for the skewed distribution
of the data, and because after log-2 transformation the regression
coefficient (b) can be interpreted as a two-fold increase in UACR.
Multiple linear regressionwas performed with UACR or eGFR as the
exposure and cardiovascular imaging parameters as the outcome.
Regression coefficients with corresponding 95% confidence in-
tervals (CI) were calculated and reflect the change in cardiovascular
outcome variable per two-fold increase in UACR or per 10ml/min/
1.73m2 change in eGFR. Analyses were adjusted for sex, age,
smoking, blood pressure, total body fat, and fasting glucose.
Sensitivity analyses were performed by excluding participants with
hypertension (blood pressure 140/90mmHg or on antihyperten-
sive treatment) or highest quintile of eGFR, indicating supra-
normal renal function (hyperfiltration). Analyses were performed
using STATA (Statacorp, College Station, Texas, USA, version 12.0)and results are presented according to the STROBE guidelines [21].
3. Results
3.1. Baseline characteristics
The total NEO study population consisted of 6671 participants.
After consecutive exclusion of participants with missing data on
carotid ultrasound (n¼ 69), urinary albumin creatinine ratio
(n¼ 27), eGFR (n¼ 50), or with macroalbuminuria (UACR >30mg/
mmol) (n¼ 22), the final cIMTgroup consisted of 6503 participants.
Of these participants, a random subset (approximately 30%) un-
derwent PWV measurement, resulting in the final PWV group of
2451 participants. Of the participants who underwent PWV mea-
surement, a second random subset of approximately 50% was
selected for additional cardiac MRI, resulting in a final cardiac MRI
group of 1308 participants (Fig. 1A). Mean (SD) age was 55.7 (6.0)
years, median UACR was 0.45mg/mmol (25th, 75th percentile;
0.30, 0.70), and mean eGFR was 86.3 (12.3) ml/min/1.73m2 in the
total group. Microalbuminuria (UACR 3e30mg/mmol or 30mg/g)
was present in 2.0% of the total group, and 0.2% of the participants
had a moderately impaired renal function (eGFR <60ml/min/
1.73m2). Self-reported history of CVD (defined as myocardial
infarction, angina, congestive heart failure, stroke and peripheral
vascular disease) was present in 6% of the total group. Participant
characteristics of the total group are provided in Table 1. Participant
characteristics of the PWV and cardiac MRI group were not
different from the total group and excluded participants were not
different from the included population (data not shown). An
overview of the cardiovascular imaging parameters is presented in
Table 2.
3.2. Associations between albuminuria and cardiovascular imaging
parameters
Table 3 shows the crude and adjusted regression coefficients
Table 1
Characteristics of the total study population.
Characteristics Total population
(n¼ 6503)
Age (years) 55.7 (6.0)
Sex (% men) 44
Ethnicity (% whites) 95
Medical history
Cardiovascular disease (%) 6
myocardial infarction 2
congestive heart failure 0.5
stroke 3
peripheral vascular disease 2
Hypertension (BP 140/90mmHg) (%) 34
Diabetes (fasting glucose >8.0mmol/L) (%) 3
Hypertriglyceridemia (fasting triglyceride 2.3mmol/L) (%) 8
Anthropometrics
Total body fat (%) in men 30.0 (6.1)
Total body fat (%) in women 36.9 (6.5)
Body mass index (kg/m2) 26.3 (4.4)








Systolic blood pressure (mmHg) 130.2 (17.0)
Diastolic blood pressure (mmHg) 83.2 (10.3)
Mean arterial pressure (mmHg) 98.9 (11.9)
Use of medication
Antihypertensives (%) 23
Glucose lowering medication (%) 3
Lipid lowering medication (%) 11
Statins (%) 11
Beta blockers (%) 11
Calcium channel blockers (%) 3
ACE inhibitors (%) 14
Diuretics (%) 8
Fasting serum measurements
Glucose (mmol/L) 5.5 (1.0)
Insulin (mU/L) 9.7 (8.1)
Triglyceride (mmol/L) 1.2 (0.8)
HDL cholesterol (mmol/L) 1.6 (0.5)
LDL cholesterol (mmol/L) 3.5 (1.0)
Total cholesterol (mmol/L) 5.7 (1.1)
Renal parameters
Creatinine (umol/L) 76.4 (14.0)
Estimated glomerular filtration rate (ml/min/1.73m2) 86.3 (12.3)
Urinary albumin excretion (mg/L) 3.62 (2.99, 4.79)
Urinary albumin-creatinine ratio (mg/mmol) 0.44 (0.30, 0.70)
Results were weighed toward the BMI distribution of the general population. Data
are shown as percentage, mean (SD) or median (25th, 75th percentile). Normal
weight: BMI<25 kg/m2, overweight: BMI 25e30 kg/m2, and obese: BMI>30 kg/m2.
ACE; angiotensin-converting-enzyme, BP; blood pressure, HDL; High-density-
lipoprotein, LDL; low-density-lipoprotein.
Cardiovascular disease was defined as myocardial infarction, angina, congestive
heart failure, stroke, and peripheral vascular disease.
Table 2
Mean (SD) of different cardiovascular imaging parameters measured in the cIMT,
PWV and cardiac MR group.
Outcome parameter n Mean (SD)
Arterial thickness 6503
Carotid intima-media thickness (mm) 0.6 (0.1)
Arterial stiffness 2451
Pulse wave velocity total (m/s) 6.6 (1.3)
Cardiovascular magnetic resonance 1138
Dimensions
LV mass (g) 99.8 (26.1)
LV mass index; LV mass/BSA (g/m2) 51.1 (10.2)
Systolic function
LV ejection fraction (%) 63.7 (5.9)
LV cardiac output (L/min) 6.2 (1.4)
LV cardiac index; LVCO/BSA (L/min/m2) 3.2 (0.6)
Diastolic function
E/A ratio 1.3 (0.5)
E deceleration peak (ml/s2* 103) 3.5 (1.1)
Results were weighed toward the BMI distribution of the general population. Data
are shown as mean (SD).
BSA; body surface area, E/A ratio; ratio of early peak filling rate and atrial peak filling
rate, UACR; urinary albumin creatinine ratio. LV hypertrophy, LV mass index
>84.1 g/m2 for men and >76.4 g/m2 for women.
Table 3
Differences (with 95% confidence intervals) in cardiovascular imaging parameters
per two-fold increase in UACR.
Imaging parameter Log2-UACR (mg/mmol)
n b 95% CI p
Carotid intima-media thickness (mm) 6503
Crude 0.006 0.00; 0.01 <0.001
Adjusted 0.003 0.00; 0.01 0.036
Pulse wave velocity (m/s) 2541
Crude 0.246 0.18; 0.31 <0.001
Adjusted 0.073 0.01; 0.13 0.015
Cardiovascular magnetic resonance 1138
LV mass index (g/m2)
Crude 0.126 0.93; 0.68 0.760
Adjusted 0.941 0.21; 1.67 0.012
LV ejection fraction (%)
Crude 0.350 0.04; 0.74 0.082
Adjusted 0.074 0.36; 0.51 0.741
LV cardiac index (L/min/m2)
Crude 0.020 0.03; 0.07 0.445
Adjusted 0.056 0.00; 0.11 0.038
E/A ratio
Crude 0.057 0.10;-0.01 0.008
Adjusted 0.031 0.06;-0.00 0.055
E deceleration peak (ml/s2*103)
Crude 0.175 0.10; 0.25 <0.001
Adjusted 0.038 0.03; 0.11 0.286
Results were weighed toward the BMI distribution of the general population. Crude
and adjusted analysis (sex, age, smoking, mean arterial blood pressure, total body fat
and fasting glucose) with linear regression coefficients and 95% confidence intervals
are shown. Regression coefficients reflect the change in cardiovascular outcome
variable with a 2-fold increase in UACR.
E/A ratio; ratio of early peak filling rate and atrial peak filling rate, UACR; urinary
albumin creatinine ratio.
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ters. In unadjusted analysis, albuminuria was associated with an
increase of 0.006mm [95% CI: 0.00, 0.01] in arterial thickness
(cIMT), which after adjustment changed to 0.003mm [95%
CI: 0.00, 0.01]. In crude analysis, a two-fold increase in UACR
arterial stiffness (PWV) was associated with an increase of 0.246m/
s [95% CI: 0.18, 0.31], which diminished after adjustment. UACRwas
not associated with LV mass index in crude analysis (b 0.126 [95%
CI: 0.93, 0.68]), however, UACR did relate to LV mass index after
adjustment for sex, and this association was attenuated after
further adjustment for the remaining confounding variables (b
0.941 [95% CI: 0.21, 1.67]). This means that per two-fold increase in
UACR, LV mass index is associated with an increase of 0.941 g/m2.UACRwas not related to LV ejection fraction in both unadjusted and
adjusted analysis. UACR was not related to LV cardiac index in the
unadjusted analysis, but after adjustment UACR did relate to LV
cardiac index (b 0.056 L/min/m2 [95% CI: 0.00, 0.11]). In unadjusted
analyses UACR was minimally associated with E deceleration peak
(b 0.175 [95% CI: 0.10, 0.25]), which diminished in adjusted ana-
lyses. Results from sensitivity analyses evaluating the associations
between albuminuria and LV mass index without participants with
hypertension (blood pressure 140/90mmHg or on antihyperten-
sive treatment) are presented in Supplementary Table 1.
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Table 4 shows the unadjusted and adjusted regression co-
efficients between renal function (per 10ml/min/1.73m2 higher
eGFR) and cardiovascular parameters. In crude analysis, renal
function was associated with a decrease of 0.004mm [95%
CI: 0.01, 0.00] of arterial thickness (cIMT) and with a decrease
of 0.149m/s [95% CI: 0.21, 0.09] of arterial stiffness (PWV).
These associations diminished after adjusting for confounding
variables. In crude analysis, renal function was associated with LV
mass index (b 0.969 [95% CI: 0.26, 1.67]) and after adjustment for
confounding variables, per 10ml/min/1.73m2 higher eGFR, LVmass
index increased with 0.748 g/m2 [95% CI: 0.15, 1.35]. Renal function
was not associatedwith LV ejection fraction in both crude (b0.374
[95% CI: 0.79, 0.04]) and adjusted analysis (b 0.294 [95%
CI: 0.72, 0.13]). In crude analysis, renal function was associated
with the LV cardiac index (b 0.08 [95% CI: 0.03, 0.13]), which
remained the same in the adjusted analysis. In crude analysis,
higher renal function was associated with an increase in the E/A
ratio (b 0.07 [95% CI: 0.03, 0.11]) and negatively associated with the
E deceleration peak (b 0.133 [95% CI: 0.20, 0.06]). These as-
sociations diminished after adjusting for confounding variables.
Results from sensitivity analyses in the cardiac MRI group, evalu-
ating the associations between renal function and LV mass index,
after exclusion of participants with hypertension (blood pressure
140/90mmHg or on antihypertensive treatment), and after
exclusion of individuals in the highest quintile of eGFR (eGFR
97.1ml/min/1.73m2), are presented in Supplementary Tables 1
and 2
4. Discussion
In this large cross-sectional study of the middle-aged generalTable 4
Differences (with 95% confidence intervals) in cardiovascular imaging parameters
per 10ml/min/1.73m2 higher eGFR.
Imaging parameters eGFR (10ml/min/1.73m2)
n b 95% CI p
Carotid intima media thickness (mm) 6503
Crude 0.004 0.01;-0.00 0.002
Adjusted 0.002 0.00; 0.00 0.137
Pulse wave velocity (m/s) 2541
Crude 0.149 0.21;-0.09 <0.001
Adjusted 0.005 0.06; 0.05 0.856
Cardiovascular magnetic resonance 1138
LV mass index (g/m2)
Crude 0.969 0.26; 1.67 0.007
Adjusted 0.748 0.15; 1.35 0.015
LV ejection fraction (%)
Crude 0.374 0.79; 0.04 0.075
Adjusted 0.294 0.72; 0.13 0.177
LV cardiac index (L/min/m2)
Crude 0.078 0.03; 0.13 0.001
Adjusted 0.080 0.03; 0.13 0.001
E/A ratio
Crude 0.07 0.03; 0.11 0.001
Adjusted 0.01 0.02; 0.05 0.449
E deceleration peak (ml/s2*103)
Crude 0.133 0.20;-0.06 <0.001
Adjusted 0.040 0.11; 0.03 0.257
Results were weighed toward the BMI distribution of the general population. Crude
and adjusted analysis (sex, age, smoking, mean arterial blood pressure, total body fat
and fasting glucose) with linear regression coefficients and 95% confidence intervals
are shown. Regression coefficients reflect the change in cardiovascular outcome
variable per 10ml/min/1.73m2 increase in eGFR. E/A ratio; ratio of early peak filling
rate and atrial peak filling rate, eGFR; estimated glomerular filtration rate according
to CKD-EPI.population, we found that normal range albuminuria and renal
function were positively associated with LV mass index and LV
cardiac index. Weak positive associations were found between
normal range albuminuria, arterial thickness, and arterial stiffness,
and no associations were observed for LV ejection fraction and
diastolic function.
We found that normal range albuminuria was independently
associated with LV mass index even after adjustment of various
confounders, such as mean arterial blood pressure and serum
glucose. In addition, subsequent sensitivity analyses, excluding all
participants with hypertension and/or using antihypertensives, did
not materially change our findings (Supplementary Table 1). Pre-
vious cardiovascular magnetic resonance-based studies, evaluating
the relationship between normo- to microalbuminuria and LVmass
in non-CKD populations, were performed solely in hypertensive
individuals [9,10], limiting conclusions on whether found associa-
tions were independent of blood pressure. Our findings are sup-
ported by the improved cardiac function and decrease in LV mass
index after renal transplantation [22,23]. Moreover, elevated
circulating levels of endothelial glycocalyx degrading enzyms, such
as syndecan-1 and thrombomodulin, have shown to normalize af-
ter kidney transplantation, indicating an improved systemic
endothelial function [24].
The observed weak positive association between eGFR and LV
mass index in our study is contra-intuitive compared to the inverse
relationship in the CKD population [25]. Previous population-based
studies, evaluating renal function measured by cystatin C rather
than eGFR, also found a positive relationship with a concentric LV
hypertrophy phenotype [3,4,26]. However, this may be confounded
by the association of cystatin C, as the endogenous cathepsin in-
hibitor with a role in adipose tissue or cardiac remodeling [27]. We
thus hypothesized this finding to be an effect of the cross-sectional
design including relatively early renal hyperfiltrate in obese sub-
jects [28]. However, exclusion of individuals within the highest
eGFR quintile did not change the observed associations, and can
thus not be clearly attributed to glomerular hyperfiltration
(Supplementary Table 2). Other explanations are the presence of a
U-shaped association or overestimation of renal function given that
the CKD-EPI formula is not validated for an eGFR >90ml/min/
1.73m2 [29].
In our study, normal range albuminuria and renal function
showed a moderately positive association with LV cardiac index,
but not with LV ejection fraction. LV cardiac index is corrected for
body surface area and heart rate in contrast to LV ejection fraction,
which does not take this into account and has a relatively larger
variance compared to LV cardiac index, making it a less sensitive
measure of LV systolic function. In the present study, no associa-
tions were demonstrated between normal range albuminuria, renal
function and LV diastolic function. These observations suggest that
the association between normal range albuminuria and LV systolic
function is more linked to physiological endothelial function than
LV diastolic function.
Vascular lipoprotein deposition and atherosclerosis have also
been linked to loss of endothelial glycocalyx, which might explain
the accelerated vascular aging in CKD, ultimately leading to sys-
temic arteriosclerosis [30,31]. Moreover, increased arterial stiffness
reflecting impaired elastic vessel properties has been observed in
the early stages of CKD, suggesting that arterial remodeling occurs
early in the disease process [32]. Older studies using tonometry
observed associations between microalbuminuria, renal function
and arterial stiffness [33,34], and in the present study, we elabo-
rated on these findings by the observed weak associations between
normal-range albuminuria, arterial thickness and arterial stiffness
in the general population.
Strengths of our study are the extensive cardiovascular imaging
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general population without contra-indications for MRI. Moreover,
previous studies have mainly used echocardiography rather than
cardiovascular magnetic resonance, which is considered the gold
standard for assessment of LV mass, volume, and function [35].
Arterial stiffness assessed by MRI is considered a superior tech-
nique regarding accuracy and precision [36,37] compared to con-
ventional tonometry. Inaccurate measurement of the pressure
wave path length by tonometry can lead to substantial measure-
ment error in PWV of up to 30% [38,39]. The use of MRI-based PWV
measurements enabled us to detect weak associations between
normal-range albuminuria and arterial stiffness in a relatively
healthy sample of the general population. The quantitative nature
of cardiovascular magnetic resonance makes this technique very
suitable for the detection of early changes in cardiovascular
morphology and functioning in large population based analyses.
There are several limitations that need to be considered. The
observational cross-sectional nature of our study precludes causal
inference. We thus cannot exclude that observed associations result
from residual confounding or reverse causation (e.g. decreased
renal perfusion and/or arterial remodeling due to lower cardiac
output). Prospective analyses with repeated measurements over
time are needed to determine the direction of the observed asso-
ciations between normal range albuminuria, renal function and
cardiovascular health. Furthermore, it should be recognized that
residual confounding by hypertension cannot be eliminated since
blood pressures levels were based on office measurements rather
than 24-h ambulatory or home blood pressure monitoring.
Although the present study is based on a study population with
oversampling of obesity, we adjusted for this by weighting all
participants towards the BMI distribution of participants from the
Leiderdorp municipality, whose BMI distribution was similar to
that of the general Dutch population. The results of the present
study, therefore, apply to a population-based study without over-
sampling of individuals with a high BMI. Another important limi-
tation is the use of estimated GFR, although the CKD-EPI formula
has proven to be more accurate and precise than the MDRD for-
mula, it has not been validated above 90ml/min/1.73m2 and might
underestimate hyperfiltration in obesity [29]. Gold standard exog-
enous clearance measurements are seldom used in epidemiological
research due to invasiveness, time and high-cost, and cystatin C
derived equations lack an international standardized calibrator.
In conclusion, normal-range albuminuria was positively asso-
ciated with LV mass index, LV cardiac index, arterial thickness and
arterial stiffness in the middle-aged general population. Our find-
ings support the hypothesis that normal range albuminuria is a
marker of cardiovascular health, even before adverse changes in the
setting of advanced kidney disease or cardiovascular disease occur.
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